# Afatinib Dimaleate (Gilotrif)

Source: https://ourhealthnetwork.com/drugs/afatinib-dimaleate
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Afatinib Dimaleate?

Afatinib Dimaleate (brand name: Gilotrif) is a kinase inhibitor. It is prescribed to treat carcinoma, non-small-cell lung, carcinoma.

## Brand names

Gilotrif

## Indications

Afatinib Dimaleate is prescribed for several conditions including carcinoma, non-small-cell lung, carcinoma, among others.

## Conditions treated

- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Non-Small-Cell Lung](https://ourhealthnetwork.com/conditions/non-small-cell-lung)
- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Squamous Cell](https://ourhealthnetwork.com/conditions/squamous-cell)

## Mechanism of action

Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the a

## Drug classification

- Established Pharmacologic Class: Kinase Inhibitor [EPC]
- Mechanism of Action class: Protein Kinase Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

decreased appetite, diarrhea, dry skin, nausea, paronychia, pruritus ( 6, rash/acneiform dermatitis, stomatitis

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)